PreMD Reports Fiscal 2005 Financial Results31 March 2006
--------------
For the year ended December 31, 2005, revenue was $1,579,000 compared with $485,000 in fiscal 2004. Product sales of PREVU(x) Skin Sterol Tests to McNeil Consumer Healthcare amounted to $426,000 in 2005 compared with $183,000 in 2004. McNeil made PREVU(x) POC available for sale in 2005 to medical professionals in Canada, the U.S. and select European markets. License revenue amounted to $1,153,000 for 2005 compared with $302,000 in 2004.
The consolidated loss for fiscal 2005 was $4,990,000 or $(0.23) per share compared with a loss of $5,569,000 or $(0.26) per share for the year ended December 31, 2004, a decrease of $579,000. This variance reflects the increase in sales and license revenue of $1,094,000, which was partially offset by an increase in interest and imputed interest of $484,000 on convertible debentures, issued on August 30, 2005.
Research and development expenditures for the year increased by $507,000 to $3,120,000 from $2,613,000 in 2004. This variance reflects:
- A $410,000 increase in spending on clinical trials for skin cholesterol
and cancer to $898,000 from $488,000 in 2004. This increase is related
to additional trials for skin cholesterol to lead to additional
regulatory approvals, a new trial for breast cancer and continuation of
the lung cancer trial (the I-ELCAP study). PreMD currently has 15
clinical trials ongoing;
- Increased legal fees on intellectual property, which amounted to
$331,000 compared with $292,000 in fiscal 2004. These costs include
$189,000 in 2005 ($96,000 in 2004) related to the petition for
reinstatement of two U.S. patents for skin cholesterol that had been
deemed abandoned;
- An increase of $135,000 in subcontract research to $451,000 in support
of the development of a second-generation color reader for the skin
cholesterol test. This was partially offset by a decrease in product
development expenditures for supplies of $55,000;
- An increase in stock-based compensation expense of $23,000, which
resulted in non-cash expenses for research personnel of $147,000 in
2005 compared with $124,000 for 2004. This reflects the amortization of
the 2003 and 2004 grants as well as the 2005 grants; and
- A decrease in compensation of $53,000, reflecting lower incentive
payments for the year for performance milestones.
General and administration expenses amounted to $2,655,000 compared with $3,355,000 in 2004, a decrease of $700,000. The decrease for the year reflects:
- A reduction of $434,000 in professional expenses resulting from the
non-recurring expenditure of $478,000 incurred in 2004 for the
unsolicited offer to acquire the shares of IBEX Technologies Inc.;
- A reduction of $54,000 in stock-based compensation for options for
administrative personnel and consultants. This resulted in a non-cash
expense of $422,000 compared with $476,000 in 2004. The 2004 amount
included $95,000 as the fair value of the cashless exercise of options
by an officer of PreMD;
- A reduction in investor relations expenses by $61,000 following the
completion of some consulting contracts during 2005;
- A reduction in compensation of $38,000, reflecting lower incentive
payments for 2005 for performance milestones; and
- A reduction of $45,000 in travel expenses as a result of fewer
international business development meetings.
Interest on convertible debentures (issued on August 30, 2005) amounted to $228,000 in 2005 compared to nil in 2004. The debentures bear interest at an annual rate of 7%, payable quarterly in either cash or stock. Imputed interest of $256,000 (compared to nil in 2004) represents the amortization of the fair value of the warrants and equity component of the debentures.
Amortization expenses for equipment and acquired technology for 2005 amounted to $210,000 compared with $224,000 in 2004. The amortization of production molds amounted to $3,000 in 2005 (2004 - $7,000), and was recorded as a cost of inventory. Purchases of equipment to support administration, clinical trials and manufacturing amounted to $130,000 in 2005 and $165,000 in 2004. Amortization of deferred financing fees amounted to $43,000 for 2005 compared to nil in 2004. The financing fees are amortized over the life of the convertible debentures.
As at December 31, 2005 PreMD had cash, cash equivalents and short-term investments totaling $8,679,000 ($5,196,000 as at December 31, 2004). Management believes that, based on historic cash expenditures and the current expectation of further revenues from product sales, royalties and license revenues, PreMD's existing cash resources together with the investment tax credits receivable of $200,000 will be sufficient to meet our current operating and capital requirements through at least 2008.
PreMD's fiscal 2005 annual report will be available on SEDAR at http://www.sedar.com and on the corporate website at http://www.premdinc.com.
About PreMD Inc.
PreMD Inc. is a world leader in predictive medicine, dedicated to developing rapid, non-invasive tests for the early detection of life-threatening diseases. PreMD's cardiovascular products, which are branded as PREVU(x) Skin Sterol Test, are licensed worldwide to McNeil Consumer Healthcare. The company's cancer tests include ColorectAlert(TM), LungAlert(TM) and a breast cancer test. PreMD's head office is located in Toronto, and its research and product development facility is at McMaster University in Hamilton, Ontario. For further information, please visit http://www.premdinc.com. For more information about PREVU(x), please visit http://www.prevu.com or call 1-866-283-8328 (North America) or 00-800-8283-8328 (Europe), or email yourvoice@mccca.jnj.com.
This press release contains forward-looking statements. These statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the successful development or marketing of the Company's products, the competitiveness of the Company's products if successfully commercialized, the lack of operating profit and availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, product liability, reliance on third-party manufacturers, the ability of the Company to take advantage of business opportunities, uncertainties related to the regulatory process, and general changes in economic conditions.
In addition, while the Company routinely obtains patents for its products and technology, the protection offered by the Company's patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates.
Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. PreMD is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
PreMD Inc.
(formerly, IMI International Medical Innovations Inc.)
Incorporated under the laws of Canada
CONSOLIDATED BALANCE SHEETS
(In Canadian dollars)
As at December 31
2005 2004
$ $
-------------------------------------------------------------------------
ASSETS
Current
Cash and cash equivalents 773,199 239,458
Short-term investments 7,905,883 4,956,945
Accounts receivable 881,891 222,348
Inventory 36,306 267,500
Prepaid expenses and other receivables 317,264 137,015
Investment tax credits receivable 200,000 389,000
-------------------------------------------------------------------------
Total current assets 10,114,543 6,212,266
-------------------------------------------------------------------------
Deferred financing fees, net of accumulated
amortization of $43,059 (2004 - nil) 477,725 -
Capital assets, net 410,636 420,955
Acquired technology, net of accumulated
amortization of $856,970 (2004 - $784,398) 290,286 362,858
-------------------------------------------------------------------------
11,293,190 6,996,079
-------------------------------------------------------------------------
-------------------------------------------------------------------------
LIABILITIES AND SHAREHOLDERS' EQUITY
Current
Accounts payable 291,125 1,021,086
Accrued liabilities 655,113 566,951
Current portion of deferred revenue 311,915 306,900
-------------------------------------------------------------------------
Total current liabilities 1,258,153 1,894,937
-------------------------------------------------------------------------
Convertible debentures 5,893,340 -
Deferred revenue 2,297,400 2,604,300
-------------------------------------------------------------------------
Total liabilities 9,448,893 4,499,237
-------------------------------------------------------------------------
Shareholders' equity
Capital stock 24,449,826 24,192,321
Contributed surplus 1,840,979 1,328,187
Equity component of convertible debentures 2,393,145 -
Warrants 1,373,718 200,000
Deficit (28,213,371) (23,223,666)
-------------------------------------------------------------------------
Total shareholders' equity 1,844,297 2,496,842
-------------------------------------------------------------------------
11,293,190 6,996,079
-------------------------------------------------------------------------
-------------------------------------------------------------------------
PreMD Inc.
(formerly, IMI International Medical Innovations Inc.)
CONSOLIDATED STATEMENTS OF LOSS AND DEFICIT
(In Canadian dollars)
Years ended December 31
2005 2004 2003
$ $ $
-------------------------------------------------------------------------
REVENUE
Product sales 425,730 183,258 -
License revenue 1,153,308 302,080 16,900
-------------------------------------------------------------------------
1,579,038 485,338 16,900
Cost of product sales,
including amortization
of $3,456 (2004-$6,600) 428,650 190,214 -
-------------------------------------------------------------------------
Gross profit 1,150,388 295,124 16,900
-------------------------------------------------------------------------
EXPENSES
Research and development 3,120,276 2,612,770 1,918,800
General and administration 2,655,056 3,355,451 2,361,602
Interest on convertible
debentures 228,481 - -
Imputed interest on
convertible debentures 255,529 - -
Amortization 252,804 224,428 280,777
-------------------------------------------------------------------------
6,512,146 6,192,649 4,561,179
-------------------------------------------------------------------------
RECOVERIES AND OTHER INCOME
Investment tax credits 198,923 205,000 223,146
Interest 173,130 123,626 258,422
-------------------------------------------------------------------------
372,053 328,626 481,568
-------------------------------------------------------------------------
Net loss for the year (4,989,705) (5,568,899) (4,062,711)
Deficit, beginning of year (23,223,666) (17,654,767) (13,592,056)
-------------------------------------------------------------------------
Deficit, end of year (28,213,371) (23,223,666) (17,654,767)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Basic and diluted loss
per share $(0.23) $(0.26) $(0.19)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Weighted average number of
common shares outstanding 21,487,008 21,276,497 20,967,677
-------------------------------------------------------------------------
-------------------------------------------------------------------------
PreMD Inc.
(formerly, IMI International Medical Innovations Inc.)
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In Canadian dollars)
Years ended December 31
2005 2004 2003
$ $ $
-------------------------------------------------------------------------
OPERATING ACTIVITIES
Net loss for the year (4,989,705) (5,568,899) (4,062,711)
Add items not involving cash
Amortization 256,260 231,028 280,777
Stock-based compensation
costs included in:
Research and development
expense 147,085 123,925 189,105
General and administration
expense 421,812 476,164 255,112
Loss on sale of capital asset - 6,098 3,873
Imputed interest on
convertible debenture 255,529 - -
Deduct gain on foreign exchange (35,734) - -
Net change in non-cash working
capital balances related to
operations (1,061,397) 544,015 (54,970)
Increase (decrease) in
deferred revenue (301,885) 2,818,100 (6,900)
-------------------------------------------------------------------------
Cash used in operating
activities (5,308,035) (1,369,569) (3,395,714)
-------------------------------------------------------------------------
INVESTING ACTIVITIES
Short-term investments (3,065,568) 1,678,190 3,326,608
Purchase of capital assets (130,310) (164,789) (385,605)
Sale of capital assets - 628 2,775
-------------------------------------------------------------------------
Cash provided by (used in)
investing activities (3,195,878) 1,514,029 2,943,778
-------------------------------------------------------------------------
FINANCING ACTIVITIES
Issuance of convertible
debentures 9,827,616 - -
Financing fees (861,328) - -
Issuance of capital stock,
net of issue costs 198,400 33,373 363,110
-------------------------------------------------------------------------
Cash provided by financing
activities 9,164,688 33,373 363,110
-------------------------------------------------------------------------
Effect of exchange rate
changes on cash and
cash equivalents (127,034) - -
-------------------------------------------------------------------------
Net increase (decrease) in
cash and cash equivalents
during the year 533,741 177,833 (88,826)
Cash and cash equivalents,
beginning of year 239,458 61,625 150,451
-------------------------------------------------------------------------
Cash and cash equivalents,
end of year 773,199 239,458 61,625
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Represented by:
Cash 773,199 173,302 61,625
Cash equivalents - 66,156 -
-------------------------------------------------------------------------
773,199 239,458 61,625
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Source: prnewswire
All trademarks and copyrighted information contained herein are the property of their respective owners.
Related Articles
|
